Edgewise Therapeutics EWTX
NASDAQ EWTX
$39.19 -0.60 (-1.51%)
At close: Sep 29, 2026 · 4:00 PM EDT

Edgewise Therapeutics (EWTX) Research & Development (2020 - 2026)

Updated

Edgewise Therapeutics' Research & Development came in at $47.55 million for Q2 2026, up 41.7% from $33.56 million a year earlier and up 11.5% from the prior quarter.

Analysis

Edgewise Therapeutics (EWTX) Research & Development (2020 - 2026) Analysis & Trends

Over the trailing twelve months to Jun 30, 2026, Edgewise Therapeutics reported Research & Development of $171.27 million, up 23.3% year-over-year; for FY2025, it was $151.39 million, up 19.2% from FY2024.

  • Research & Development has increased in each of the last five years, with a five-year compound annual growth rate of 58.8% (FY2020 to FY2025).
  • Going back by year, Research & Development was $126.97 million in FY2024 (+39.7%), $90.91 million in FY2023 (+68.2%), $54.03 million in FY2022 (+67.9%) and $32.19 million in FY2021 (+114.8%).
  • The Q2 2026 figure represents the highest quarterly Research & Development in data going back to Q1 2020.
  • Year-over-year, Research & Development has increased for 22 consecutive quarters, with growth averaging 25.4% over the last eight quarters.
  • Over the past five years, the year-over-year growth in Research & Development ranged from 9.4% (Q2 2025) to 205.1% (Q3 2021).
  • Business Quant data shows EWTX's Research & Development at $42.65 million (Q1 2026), $43.59 million (Q4 2025) and $37.48 million (Q3 2025) in the three quarters before Q2 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) R&D (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn 3.65 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn 2.34 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn 9.74 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn -2.85 Bn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn -4.05 Bn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn 1.87 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn 1.76 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 2.81 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn 993.80 Mn
10 Edgewise Therapeutics 4.29 Bn 4.29 Bn - 47.55 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 47.55 Mn
Mar 31, 2026 42.65 Mn
Dec 31, 2025 43.59 Mn
Sep 30, 2025 37.48 Mn
Jun 30, 2025 33.56 Mn
Mar 31, 2025 36.76 Mn
Dec 31, 2024 36.37 Mn
Sep 30, 2024 32.22 Mn
Jun 30, 2024 30.68 Mn
Mar 31, 2024 27.69 Mn
Dec 31, 2023 27.68 Mn
Sep 30, 2023 23.79 Mn
Jun 30, 2023 19.56 Mn
Mar 31, 2023 19.88 Mn
Dec 31, 2022 16.61 Mn
Sep 30, 2022 13.89 Mn
Jun 30, 2022 12.40 Mn
Mar 31, 2022 11.12 Mn
Dec 31, 2021 9.09 Mn
Sep 30, 2021 9.88 Mn
API Access

Edgewise Therapeutics Research & Development API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=research-and-development&ticker=EWTX&period=max&api_key=YOUR_API_KEY